International Journal of Clinical Oncology and Cancer Research
Volume 4, Issue 6, December 2019, Pages: 45-48
Received: Sep. 16, 2019;
Accepted: Nov. 13, 2019;
Published: Nov. 20, 2019
Views 30 Downloads 11
Olufunmilade Omisanjo, Department of Surgery, Lagos State University College of Medicine, Ikeja, Nigeria; Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Olawale Ogunremi, Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Olufemi Ojewuyi, Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Olufemi Akinola, Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Fatai Balogun, Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Stephen Ikuerowo, Department of Surgery, Lagos State University College of Medicine, Ikeja, Nigeria; Department of Surgery, Lagos State University Teaching Hospital, Ikeja, Nigeria
Background: Though prostate biopsy is generally a safe procedure, it can be associated with complications. It is important to document the complication rates and identify potential risk factors for these complications. The aim of this study was therefore to investigate the complication rates following prostate biopsy at the Lagos State University Teaching Hospital Ikeja Lagos Nigeria over a 5 year period from January 2012 to December 2016. Patients and Methods: This was a retrospective study in which the clinical records of all the patients who had prostate biopsy at the Lagos State University Teaching Hospital Ikeja, Lagos Nigeria over a 5 year period between January 2012 and December 2016 were retrieved and analyzed. Results: The clinical records of a total of 258 patients were available for review. The mean age was 68.2years (range 45 to 81years). The mean and median PSA values were 560ng/ml and 57ng/ml respectively (range 2.05 to 15,400ng/ml). The prostate biopsy was transrectal and digitally guided in all cases. All the patients had empirical intravenous prophylactic antibiotics with intravenous ciprofloxacin 500mg stat and were discharged on oral ciprofloxacin 500mg bd and oral metronidazole 400mg tds for one week. All the patients had a caudal block. One hundred and seventeen (45.3%) had a comorbidity. The mean prostate size was 109gms (range 16 – 146gms). The size of the trucut needle used was size 16 in 121 patients (46.9%) and size 18 in 125 patients (48.4%). The mean number of biopsy cores taken was 10 (range 4 to 15). The histological diagnosis was carcinoma of the prostate in 154 patients (59.7%) and benign prostatic hyperplasia in 100 patients (38.8%). Twenty four patients (9.3%) had complications. The complications were sepsis (3.1%), rectal bleeding (2.3%), haematuria (2.3%) and acute urinary retention (1.6%). Thirteen patients needed hospitalization (5%). There was no mortality. The incidence of sepsis was statistically significantly higher with increasing the number of cores taken (p=0.000), but there was no significant difference in the incidence of sepsis with the size of the trucut needle used (p= 0.299) or the presence of morbidity (p = 0.503). Conclusion: Though the complication rates following prostate biopsy remain low, increasing number of prostate cores taken is a risk factor for adverse events. We therefore recommend reducing the number of prostate cores taken in patients with advanced prostate cancer with high tumour volume in order to further reduce the risk of prostate biopsy complications in our environment.
Complications Following Prostate Biopsy: A Single Centre Five Year Review, International Journal of Clinical Oncology and Cancer Research.
Vol. 4, No. 6,
2019, pp. 45-48.
Parkin DM, Bray F, Ferlay J, Pisani P. Estimates of worldwide burden of cancer in 2002, Globocan 2002. CA Cancer J Clin. 2005; 55 (2): 74–108.
Ogunbiyi JO, Shittu OB. Increased incidence of prostate cancer in Nigeria. Journal of National Medical Association 1999; 91 (3): 159-164.
Scherr DS, Eastham J, Ohori M, et al. Prostate biopsy techniques and indications: when, where, and how? Semin Urol Oncol. 2002; 20: 18-31.
Smeenge M, de la Rosette JJ, Wijkstra H. Current status of transrectal ultrasound techniques in prostate cancer. Curr Opin Urol. 2012; 22: 297-302.
Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011; 5: CD006576.
Liss MA, Chang A, Santos R, et al. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol 2011; 185: 1283.
Ecke TH, Gunia S, Bartel P, et al. Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. Urol Oncol. 2008; 26: 474-478.
Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 2011; 186: 1830-1834.
Badmus TA, Adesunkanmi AR, Yusuf BM et al. Burden of prostate cancer in southwestern Nigeria. Urology 2010; 76 (2): 412-6.
Udeh E. I, Amu O. C., Nnabugwu I. I., Ozoemena O. F. N. Transperineal versus tranrectal prostate biopsy: our findings in a tertiary health institution. Nigerian Journal of Clinical Practice. 2015: 18 (1); 110-114.
Shittu O. B, Kamara T. B. Transrectal biopsy of the prostate gland in Ibadan. The Nigerian Journal of Surgical Research. 2001: 3 (4); 159-164.
Eke N. Antibiotics prophylaxis for digital-guided transrectal tru-cut needle biopsy of the prostate. West Afr J Med. 2006; 25 (4): 262-265.
Okeke LI. Day case transurethral prostatectomy in Nigeria. West Afr J Med. 2004 Apr-Jun; 23 (2): 128-30.
Ikuerowo SO, Popoola AA, Olapade-Olaopa EO, Okeke LI, Shittu OB, Adebayo SA, Sanusi AA. Caudal block anesthesia for transrectal prostate biopsy. Int Urol Nephrol. 2010 Mar; 42 (1): 19-22. Epub 2007 Feb 22.
Wang N, Fu Y, Ma H, Wang J, Gao Y. Advantages of caudal block over intrarectal local anesthesia plus periprostatic nerve block for transrectal ultrasound guided prostate biopsy. Pak J Med Sci. 2016 Jul-Aug; 32 (4): 978-82. doi: 10.12669/pjms.324.9823.
Son KC, Chung HS, Jung S, Kim MS, Hwang EC, Kim JW, Kwon DD. Trial Comparing a Combined Regimen of Amikacin and Ciprofloxacin to Ciprofloxacin Alone as Transrectal Prostate Biopsy Prophylaxis in the Era of High Fluoroquinolone-Resistant Rectal Flora. J Korean Med Sci. 2018 Apr 9; 33 (15): e113.
Cicione A, Cantiello F, De Nunzio C, Tubaro A, Damiano R. Prostate biopsy quality is independent of needle size: A randomized single‑center prospective study. Urol Int 2012; 89: 57‑60.
Chiang IN, Chang SJ, Pu YS, et al. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc. 2007; 106: 929-934.
Lange D, Zappavigna C, Hamidizadeh R et al. Bacterial sepsis after prostate biopsy- a new perspective. Urology 2009; 74: 1200.
Simsir A, Kismali E, Mammadov R, et al. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int. 2010; 84: 395-399.
Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998; 160: 2115-2120.
Djavan B, Waldert M, Zlotta A, et al: Safety and morbidity of first and repeat transrectal ultrasound-guided prostate needle biopsies: Results of a prospective European prostate cancer detection study. J Urol 2001; 166: 856-860.
Donovan, J., et al. Prostate Testing for Cancer and Treatment (Protec T) feasibility study. Health Technol Assess, 2003. 7: 1.
Brewster DH, Fischbacher CM, Nolan J, Nowell S, Redpath D, Nabi G. Risk of hospitalization and death following prostate biopsy in Scotland. Public Health. 2017 Jan; 142: 102–110.